Introduction
Prostate cancer (PCa), is the second most common malignancy in men worldwide (only behind lung cancer), accounting for over 1,400,000 new cases annually, and causing around 350,000 mortalities [
1,
2]. PCa often affects the older males with ages over 50 years [
3]. Although PCa usually evolves slowly during the early stages, metastatic progression severely worsens patient prognosis and leads to death [
4]. Hence, new therapies that target advanced disease are urgently needed.
Serum prostate-specific antigen (PSA) measurements are widely utilized in PCa diagnosis, but the specificity of PSA testing is unfortunately poor, the positive predictive value of PSA is only 24–37% [
5‐
7]. Single use of PSA testing leads to overdiagnosis and overtreatment, so its extensive use is not recommended. Therefore, basic research has been focused on searching for new biomarkers able to provide the efficient diagnosis and to predict cancer progression.
MicroRNAs (miRNAs) are a kind of non-coding RNAs with 22–25 nucleotides encoded by endogenous genes. MiRNAs have been reported involving in the initiation and progression of PCa [
8], such as miR-222 [
9,
10], miR-141 [
11,
12], miR-145 and miR-148 [
13,
14]. MiR-183-5p is a recently discovered cancer-related miRNA, which has been confirmed to be an oncogenic role in PCa [
15‐
18]. Studies reported that the expression of miR-183-5p in prostate biopsy was correlated with tumor status and prognosis [
19,
20]. Moreover, miRNA-183 expression could also reduce tumor cell adhesion of PCa [
21]. Furthermore, miR-183 positively regulated the level of prostate-specific antigen (PSA) in serum and it might be used as a prognostic marker of diagnosis progression of PCa [
15,
22,
23]. Similarly, in our previous experiments, we found the expression of miR-183-5p was up-regulated in PCa tissues.
TET1 is a member of the Ten-eleven-translocation enzymes (TETs) family. It is a DNA demethylase that hydroxylates 5-methylcytosine (5mC) to 5-hydroxymetylcytosine (5hmC), thereby facilitates active DNA demethylation [
8,
24]. Studies confirmed that abnormalities in DNA methylation are crucial in tumor formation, and the dysregulation of TET1 level was found in multiple malignancies such as gastric, lung, breast cancer [
25‐
29]. Though reduction of TET1 expression in most tumors was once considered a hallmark of cancer, recent studies have shown that high TET1 expression was associated with tumor grade and poor outcome in triple-negative breast cancer (TNBC) [
30]. All these results suggest that TET1 may serve as both an oncogenic role and a tumor suppressor.
In our study, we hypothesize that miR-183-5p could promote migration and invasion of PCa by regulating the target gene TET1, thereby exacerbating the process of PCa.
Materials and methods
PCa tissues samples
A total of 12 prostate cancer tissues and their paired adjacent tissues were collected from patients undergoing the radical prostatectomy at the Third Affiliated Hospital of SooChow University from Jun 2019 to Dec 2019. Patients enrolled in this study received no preoperative radiotherapy and/or chemotherapy. Each tissue was snap-frozen immediately in liquid nitrogen after excision, and stored at -80ºC until use.
Gene expression and clinicopathological features of patients with prostate cancer in PRAD-TCGA were downloaded from UCSC Xena Cancer browser (
https://xenabrowser.net). Microarray datasets (GSE21036 and GSE64318) containing miR-183-5p expression profiles of prostate biopsy samples (52 cancer tissues and 52 adjacent tissues) were downloaded from Gene Expression Omnibus (GEO) (
https://www.ncbi.nlm.nih.gov/gds/). SPSS17.0 (Chicago, IL, USA) and GraphPad Prism 5.0 (San Diego, CA, USA) software was used for the statistical analysis. Moreover, TargetScan, miRDB, miRWalk and StarBase were used to predict miR-183-5p target genes.
Cell lines and transfection
Human PCa cell lines, including androgen-dependent LNCaP and androgen-independent PC-3, were obtained from the Cell Bank of the Committee on Type Culture Collection of the Chinese Academy of Sciences. Cells were cultured in F12K or RPMI-1640 medium (Gibco, Carlsbad, CA) containing 10% fetal bovine serum (BI, Israel) at 37ºC with 5% CO2.
MiR-183-5p mimics, mimics negative control (miR-NC), miR-183-5p inhibitor and inhibitor NC were purchased from GenePharma (GenePharma, Shanghai, China). Cells were seeded in 6-well plates and grown to a density of 40–60%, then transfection was performed using Lipofectamine 2000 (Invitrogen, CA, USA) according to the manufacturer’s instructions, respectively. And these cells were harvested for verification of transfection efficacy after 48 h.
CCK-8 assay
Cells were seeded in a 96-well plate at a density of 1 × 104 cells/well, and culture medium was used as a blank control. CCK-8 was added to each well (six replicate wells per group) at the indicated time points (10 µl/well), and the absorbance at 450 nm was measured 2 h later to estimate viable cells using an automatic plate reader.
Cell migration and invasion assay
A transwell chamber with an 8-µm pore size polycarbonate membrane (Corning, NY) was used to evaluate cell migration. After 48 h of transfection, the PCa cells were resuspended with basic medium and seeded into the upper chamber (2 × 104 for PC-3 cells and 5 × 104 for LNCaP cells), while culture medium containing 15% FBS was added to the lower chamber. After incubation for 48 h at 37 °C, the medium was removed from the upper chamber, and non-migrated cells were scraped off with a cotton swab. The migrated cells on the other side of the membrane were fixed in 4% paraformaldehyde for 30 min, stained with crystal violet for 15 min, and counted under an inverted microscope at 200x magnification in at least three randomly selected fields.
In the invasion assay, the upper chamber was pre-coated with 10% Matrigel (BD Biosciences, San Jose, CA, United States) and the procedures of the cell invasion assay were identical to the cell migration assay.
Wound healing assay
Transfected cells were plated into 6-well plates and grown to 90% confluence. A 10 µl sterile pipette tip was used to create a scratch wound across cell monolayer, then detached cells and debris were removed by PBS, and the attached cells were incubated in the medium with 1% FBS. Images of the wound closure was captured at 0 and 48 h using the microscope.
Luciferase reporter assay
To verify whether miR-183-5p directly binds to the 3’UTR of TET1, luciferase reporter assay was performed. MiR-183-5p mimics or mimics negative control (NC) were transfected into HEK293T cells together with TET1 (wild type (WT) or mutant (MUT)) using lipofectamine 2000 (Invitrogen), respectively. The relative luciferase activities were measured using a detection kit (Promega Corp, USA) after 48 h, according to the manufacturer’s instructions.
Western blot analysis
The cells were harvested and lysed using protein RIPA buffer (Beyotime, Shanghai, China) supplemented with protease inhibitor and phosphatase inhibitor (Thermo Fisher Scientific, USA). The protein concentration was determined by the BCA protein assay kit (Beyotime, Shanghai, China). Samples were mixed with SDS-PAGE loading buffer (Beyotime, Shanghai, China) and separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). After transferring onto polyvinylidene difluoride (PVDF) membranes (Merck Millipore, Billerica, MA, USA), the membranes were blocked with 5% skim milk in TBST at room temperature for 1 h, and then incubated with anti-TET1(MA5-16312, 1:1000 dilution, Thermo Fisher Scientific) or anti-β-actin (ARG65683, 1:1000 dilution, Arigo) antibodies for 2 h, followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG for 1 h. Protein bands were visualized by an ECL + Plus western blotting detection system (CW Biotech, Beijing, China) and quantified using a scanner with Quantity One software (Version 4.2.1, Bio-Rad Laboratories, Hercules, CA, USA).
Total RNA extraction and real-time PCR (qRT‐PCR)
Total RNA was extracted from PCa cell lines and clinical tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed into cDNA using the RevertAid™ first strand cDNA synthesis kit (Thermo Fisher Scientific, USA). The obtained cDNA was subjected to qRT-PCR by performing on a LightCycler480®II in a final volume of 25 µL. Optimum reaction conditions were obtained with 0.04 µL of 100 µM of each primer and probe, 2.5 µL of 10× PCR buffer, 2.5 µL of 25 mM MgCl
2, 0.5 µL of 10 mM 4× dNTPs, 0.25 µL of 5 U/µL Taq DNA polymerase, and 2 µL template cDNA. Finally, 17.13 µL ddH
2O was added to the reaction mixture. The mixture was preheated at 95ºC for 3 min to activate Taq polymerase, followed by 40 cycles at 95ºC for 5 s and 60ºC for 15 s. Samples were amplified simultaneously in triplicate in one assay run. Data were normalized to GAPDH or U6. Sequences of primers and probes are summarized in Table
1.
Table 1
Sequences of primers and probes for real-time RT-PCR
miR-183-5p | Forward | CCTGTTCTGTGTATGGCACTGGT |
Reverse | TTCACTGACTGAGACTGTTCACAGTG |
Human TET1 | Forward | CCATCTGTTGTTGTGCCTCTG |
| Reverse | GCCATTTACTGGTTTGTTGTCA |
| Probe | FAM-AGGTTATAAAGGAAAACAAGAGGCCCC-BHQ-1 |
Human GAPDH | Forward | CAACTACATGGTTTACATGTTC |
Reverse | GCCAGTGGACTCCACGAC |
Probe | CY5-TTTGGTCGTATTGGGCGCCTG-BHQ-1 |
Statistically analysis
Data were presented as mean ± S.E.M., and GraphPad Prism (version 5.0) was used for data analyses.
The paired Student’s t-tests were performed to compare two related samples, while the unpaired Student’s t-tests were used to compare differences between different groups. A one-way ANOVA test was conducted to compare the intergroup difference more than two groups. Kaplan– Meier curves were introduced for survival analysis. P value less than 0.05 was considered as statistically significant.
Discussion
The present study aimed to investigate the regulatory role of miR-183-5p and its potential target TET1 in the progression of PCa. In clinical studies, we found that miR-183-5p was up-regulated in PCa tissues, moreover, PCa patients with high miR-183 expression had shorter recurrence-free survival than those with low miR-183 expression. While in functional studies, we observed that overexpression of miR-183-5p promoted the migration and invasion of PCa cells, both LNCaP and PC3 cells. Meanwhile, miR-183-5p down-regulated the expression of TET1 protein in cells. On the contrary, inhibit miR-183-5p retarded migration and invasion processes of PCa cells and increase the expression of TET1 protein. By constructing a luciferase reporter vector, we determined that TET1 was a direct target of miR-183-5p.
MiR-183-5p is located on chromosome 7q31-34, which is a member of the miR-183-96-182 cluster. This cluster includes miR-183, miR-96 and miR-182, the three members have highly homologous sequence. The miR-183-96-182 cluster was originally identified as a sensory organ-specific miRNA cluster, including hearing, vision and olfaction [
28,
29,
31,
32]. However, recent studies have demonstrated that the miR-183-96-182 cluster was involved in oncogenesis and cancer progression[
33]. Among them, miR-183-5p was reported highly expressed in renal cell carcinoma, non-small cell lung cancer and breast cancer, and promoted malignant progress, even resulting in radioresistance [
34‐
37]. Consistent with above, miR-183-5p was found overexpression in PCa tissues and it positively regulated serum levels of PSA, which functioned as an oncogene in PCa [
15,
38]. This conclusion was further supported by our findings in this study. Moreover, our findings show for the first time that miR-183-5p can also directly modulate TET1 expression in PCa, which suggesting that miR-183-5p may affect tumorigenesis and progression through DNA methylation.
TET1 has been recognized as a tumor suppressor in a variety of human cancer[
39,
40]. It had been verified that the protein and mRNA levels of TET1 were decreased in PCa, and low TET1 mRNA levels correlated significantly with a wore metastasis-free survival[
41]. In addition, in xenograft models, TET1 deficiency facilitated tumor growth and metastasis[
42]. These results implied that TET1 might participate in the pathogenesis of PCa. Carolina et al. showed that miR-183-5p could strengthen the ability of PCa cells to adhesion via repression of ITGB1 expression[
21]. Here we found that overexpression of miR-183-5p enhanced the malignant phenotype of PCa cells by inhibiting TET1 expression. Our studies have further confirmed that miRNAs and their target genes did not have a one-to-one correspondence, at times, one miRNA would target different mRNAs, and one target mRNA would be regulated by serval miRNAs in the same human tumor.
But there were still some findings not in accord with the expectation. We found up-regulation of miR-183-5p promoted the migration and invasion of PCa cells, but did not affect cell proliferation. However, Larne et al. found that overexpression of miR-183 induced cell growth in PCa cells[
15]. We suspect that this may be due to distinct biological effects of miR-183-5p and miR-183-3p.Two mature miRNAs, deriving from 3’ and 5’ ends of the same pre-miRNA, may induce different effect in proliferation, migration and invasion[
43]. Ling et al. reported that phoenixin-14 regulated proliferation and apoptosis of vascular smooth muscle cells by activating KCNQ1OT1/miR-183-3p/CTNNB1 pathway, which partly confirmed our speculation[
44]. Nevertheless, it is true that more research is needed to definite the biological functions of the miR-183 hairpin RNA products, respectively, in order to obtain a better understanding of the regulatory mechanism of miR-183 in PCa.
Briefly, miR-183-5p promotes the migration and invasion of PCa cells, and high expression of miR-183 is associated with poor prognosis of PCa patients. In addition, miR-183-5p targeting TET1 may be a new potential biomarker for PCa.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.